Problem statement

• Global – quality ignores market realities
  • WHO promotes quality over everything
  • WHO PQ/ERP/SRA required for UNFPA procurement

• Country – price can ignore quality
  • Governments are less interested in quality, but more interested in price*

* Low price does not assume low quality, desire to save money does not mean a disregard for quality
WHO Pre qualification programme

Invitation

Dossier
Gems keep AAWG appraised of status

Inspection
Who is in the inspection teams?

Decision
How can AAWG bring product to market?
Challenges and advocacy targets

- Political will – ARVs versus RH commodities (includes MA products)
  - What can we learn from the HIV sector?
  - New advocacy targets – WTO, (TRIPS), private sector, huge investments to bring new products to market
- Increased collaboration with GEMS – status of pipeline products

- Speed, several months v several years
  - Can manufacturers be given more support for the process?

- Case of Levonoplant
  - Approved for 3 years
  - Research study (methodology WHO approved) found 4 years duration
  - Approved for 3 years
  - Lack of transparency
• Progress - UNFPA supplies ordering in formulations!

• Pricing – variable - innovators higher than generic
  Innovator price displayed – dis-incentive to procure the cheaper product

• Where does resistance lie?
• 2014-2015 increase from $145m to $805m, 2016 data to date indicates a potential decrease. Why?

• Costings tool to support procurement of generics
National Ministry of Health

• Who decides what products are procured?

• Transparency of process and decision-making - lack of

• Procurement guidelines – UNFPA requires ERP

• Potential advocacy platforms
  • Technical working group
  • RH CS group
  • Advocacy targets:
    • MoH, Mo Finance – value for money
    • National pharmaceuticals board
What next?

• Transparency
  • We need to learn more and more neds to be put into the public domain particularly about the WHO PRP

• Learn from the HIV movement

• We need new partners governance and transparency
• Access to medicines

• Increased collaboration and information sharing with GEMS